Longevity - How to Die Young at a Very Old Age

See the Program
Our Program on display
Track Co-Chairs: 
Anat Naschitz Managing Director, OrbiMed Advisors
Nir Barzilai, MD Rennert Professor of Aging, Albert Einstein College of Medicine
Yael Benvenisti, PhD CEO, Mediterranean Towers Ventures
9:00 - 9:30
Yael Benvenisti, PhD CEO, Mediterranean Towers Ventures Mediterranean Towers Ventures: “Welcome and overview”
9:30 - 9:45
Nir Barzilai, MD Rennert Professor of Aging, Albert Einstein College of Medicine Mediterranean Towers Ventures: “Welcome and overview”

invited speakers in file – after lunch is company presentations – TBC & and not yet for publication

Lunch Break

Steve Engle, CEO, Cohbar Therapeutics: “Mitochondria and aging – 1”

Natalie Ohana, Founder and CEO, Minovia: “Mitochondria and aging – 2”

Tal Dvir, Matricelf: “What if we could 3D print a heart? Well, we can”

Shai Efrati, Director of the Sagol Center at Shamir Medical Center (Assaf HaRofeh): “Hyperbaric chamber therapy”

Meditemi: “Aa robot will take care of your parents”

xrhealth: “AR/VR in the service of cognition and pain”

TBD

TBD: “So, can we live forever? Challenging the approaches shared today”

Track Co-Chairs:
Anat Naschitz Managing Director, OrbiMed Advisors
Nir Barzilai, MD Rennert Professor of Aging, Albert Einstein College of Medicine
Yael Benvenisti, PhD CEO, Mediterranean Towers Ventures
Yael Benvenisti, PhD CEO, Mediterranean Towers Ventures “Welcome and overview”
Nir Barzilai, MD Rennert Professor of Aging, Albert Einstein College of Medicine “Conquering the challenges of targeting aging”
Mehmood Kahn CEO, Life Biosciences “Aging focused drug development – making it work”
Steve Austad, PhD Distinguished Professor and Chair of the Dept of Biology, University of Alabama at Birmingham “What can we learn from aging focused preclinical trials?”
James Peyer, PhD Founder and Managing Partner, Kronos BioVentures “How does the biotech of aging differ from the biotech we know?”
Joan Mannick, MD Chief Medical Officer, resTORbio “The cautionary tale of a phase 3 asset targeting longevity”
Zan Fleming, MD Founder and Executive Chairman, Kinexum “The regulatory challenges associated with longevity oriented drug development”
Prof. Eran Segal, PhD Department of Computer Science and Applied Math, Weizmann Institute “Microbiome, nutrition and longevity”
Rafael de Cabo, PhD, Senior Investigator, Translational Gerontology Branch, NIH “Intermittent Fasting – less is more…”
Lunch Break